Have you ever noticed that when an adult over 40 starts on both meal-time and long-acting insulin, they will refuse to acknowledge that they could possibly have developed type 1 diabetes? Since most of those patients will never see an endocrinologist and have an antibody test, they will never really …

As noted in our Editor's Letter, David Joffe discusses the importance of how we talk with patients. And to that I'll add...how or if we listen to our patients. David's letter made me think about what we say to patients when they are at risk, when they are diagnosed, and during the treatment phase. If we keep current with our knowledge of diseases — in this case, diabetes — and share what we know today but be clear that we may learn more and differently in the future, the patient may be more open to accept changes and work toward their health goals while at the same time taking into consideration what is known and currently available.

John Buse, MD, PhD, is the director of the North Carolina Translational and Clinical Sciences Institute and of the UNC Diabetes Center for Excellence, professor of Medicine and Executive Associate Dean for Clinical Research at the UNC School of Medicine. His specialty is the prevention and treatment of type 1 diabetes and type 2 diabetes, and their complications. Dr. Buse’s practice combines clinical care, research and education.

In this week's Homerun Slides, more on the diabetes app as a tool to streamline processes and save time as well as money.

Type 1 diabetes (T1DM) is a chronic autoimmune disease in which the beta cells of the islets of Langerhans are selectively destroyed, resulting in insulin deficiency and hyperglycemia. The disease develops in genetically susceptible individuals, most likely as a result of an environmental trigger. T1DM has an uneven geographical distribution; disease prevalence is highest in populations of white European origin and lowest in those of East Asian descent. A marked gradient in disease risk also exists in Europe, with higher prevalence of T1DM in northern countries, particularly Finland, compared with areas around the Mediterranean. This pattern could be attributed to genetic differences between the populations or to the presence/absence of environmental triggers.

In this Exclusive Interview transcript John Buse talks with Diabetes in Control Publisher Steve Freed during the ADA 2018 convention in Orlando about the Observe 4D real-world study on SGLT2 Inhibitors.

In this Exclusive Interview, John Buse talks with Diabetes in Control Publisher Steve Freed during the ADA 2018 convention in Orlando about the Observe 4D real-world study.

In part 1 of this Exclusive Interview, John Buse talks with Diabetes in Control Publisher Steve Freed about his excitement over the information presented at the ADA conference about the GLP-1 and SGLT-2 drugs, and how to implement their use.

In part 2 of this Exclusive Interview, John Buse explains the Observe 4D real-world study, which looked at the relationship between the use of SGLT-2 and heart failure and amputation outcomes, in a conversation with Diabetes in Control Publisher Steve Freed.

In part 3 of this Exclusive Interview, John Buse talks with Diabetes in Control Publisher Steve Freed about the heart complication and amputation risks on the greater population.